Literature DB >> 23422053

Antidepressants and QTc prolongation.

Raymond W Lam1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23422053      PMCID： PMC3581598          DOI： 10.1503/jpn.120256

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  8 in total

1.  Torsade de Pointes episodes under treatment with selective serotonin reuptake inhibitors.

Authors:  K Wenzel-Seifert; M Wittmann; E Haen
Journal:  Pharmacopsychiatry       Date:  2010-10-06       Impact factor: 5.788

Review 2.  Drug-induced arrhythmias.

Authors:  Brian J Barnes; James M Hollands
Journal:  Crit Care Med       Date:  2010-06       Impact factor: 7.598

3.  A critical evaluation of the cardiac toxicity of citalopram: part 1.

Authors:  Robert H Howland
Journal:  J Psychosoc Nurs Ment Health Serv       Date:  2011-10-19       Impact factor: 1.098

Review 4.  Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?

Authors:  W Victor R Vieweg; Mehrul Hasnain; Robert H Howland; John M Hettema; Christopher Kogut; Mark A Wood; Ananda K Pandurangi
Journal:  Am J Med       Date:  2012-06-27       Impact factor: 4.965

5.  Drug-induced proarrhythmia and use of QTc-prolonging agents: clues for clinicians.

Authors:  E Kevin Heist; Jeremy N Ruskin
Journal:  Heart Rhythm       Date:  2005-11       Impact factor: 6.343

Review 6.  QT alterations in psychopharmacology: proven candidates and suspects.

Authors:  Paulino Antonio Alvarez; Jaime Pahissa
Journal:  Curr Drug Saf       Date:  2010-01

Review 7.  Antipsychotic drugs and QT prolongation.

Authors:  Claudia Stöllberger; Johannes O Huber; Josef Finsterer
Journal:  Int Clin Psychopharmacol       Date:  2005-09       Impact factor: 1.659

8.  Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial.

Authors:  Jamal A Hanash; Baiba H Hansen; Jørgen F Hansen; Olav W Nielsen; Alice Rasmussen; Morten Birket-Smith
Journal:  J Cardiovasc Pharmacol       Date:  2012-10       Impact factor: 3.105
  8 in total
  6 in total

Review 1.  Physical Health and Drug Safety in Individuals with Schizophrenia.

Authors:  Tamara Pringsheim; Martina Kelly; Doug Urness; Michael Teehan; Zahinoor Ismail; David Gardner
Journal:  Can J Psychiatry       Date:  2017-07-18       Impact factor: 4.356

2.  Escitalopram and QTc prolongation.

Authors:  Mehrul Hasnain; Robert H Howland; W Victor R Vieweg
Journal:  J Psychiatry Neurosci       Date:  2013-07       Impact factor: 6.186

Review 3.  Serotonin Selective Reuptake Inhibitors (SSRIs) and Stroke.

Authors:  F Chollet; J Rigal; P Marque; M Barbieux-Guillot; N Raposo; V Fabry; J F Albucher; J Pariente; I Loubinoux
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-23       Impact factor: 5.081

4.  Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.

Authors:  Christopher Pittenger; Brian P Brennan; Lorrin Koran; Carol A Mathews; Gerald Nestadt; Michele Pato; Katharine A Phillips; Carolyn I Rodriguez; H Blair Simpson; Petros Skapinakis; Dan J Stein; Eric A Storch
Journal:  Psychiatry Res       Date:  2021-03-04       Impact factor: 11.225

5.  Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study.

Authors:  Elena Qirjazi; Eric McArthur; Danielle M Nash; Stephanie N Dixon; Matthew A Weir; Akshya Vasudev; Racquel Jandoc; Lorne J Gula; Matthew J Oliver; Ron Wald; Amit X Garg
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

6.  Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials.

Authors:  Natasha Chawla; Thunyarat Anothaisintawee; Kridsada Charoenrungrueangchai; Papan Thaipisuttikul; Gareth J McKay; John Attia; Ammarin Thakkinstian
Journal:  BMJ       Date:  2022-01-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.